Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiary

February 9, 2023
Takeda Completes Acquisition of Nimbus TYK2 Subsidiary image

Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion.

Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nimbus as NDI-034858. With Phase 2b data to be presented in the fourth quarter of FY2022 and Phase 3 study in psoriasis expected to start in 2023, TAK-279 has the potential to demonstrate best-in-class efficacy, safety and convenience in psoriasis, according to a Takeda news release. The drug candidate is also being evaluated in multiple other immune-mediated diseases, including inflammatory bowel disease, psoriatic arthritis, and systemic lupus erythematosus.

“With our plan to acquire announced in December, we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline,” Ramona Sequeira, president, global portfolio division, at Takeda, said in a company news release. “This program closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”

Under the terms of the agreement, Takeda will pay Nimbus approximately $4 billion upfront, plus two milestone payments to Nimbus of $1 billion each upon achieving annual net sales of $4 billion and $5 billion of products developed from the TAK-279 program.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free